Clinic
DRS Ergent Care, LLC
DRS Ergent Care, LLC was paid $2.11M by Medicaid between Apr 2020 and May 2022, across 28 billing codes. Its largest line is 99204, doctor's office visit, new patient (more involved) — 32% of everything it billed.
33Billing provider infoDRS ERGENT CARE, LLC
GAMBRILLS, MD 21054
GAMBRILLS, MD 21054
33aNPI1780039818assigned 04/26/2016
33bProvider typeUrgent Care Clinic/Center
28Total paid$2.11M
24GClaims32,541
24DCodes billed28
24AFirst – last monthApr 2020 – May 2022
Compared with peers
Next to other Urgent Care Clinic/Center providers in Maryland
Rank by total paid#38 of 114
Median peer was paid$654K
This provider vs. median3.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 7,325 | $391K | |
| 2021 | 21,532 | $1.46M | |
| 2022 | 3,684 | $265K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 32% | 7,188 | 6,500 | $680K |
| S9083 | Global fee urgent care centers | 17% | 3,399 | 2,531 | $356K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 13% | 2,930 | 2,516 | $267K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 9.5% | 3,483 | 2,755 | $201K |
| 87428 | 8.1% | 3,185 | 2,873 | $170K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 6.8% | 4,700 | 4,146 | $144K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 4.2% | 2,303 | 2,134 | $89K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2.8% | 1,147 | 957 | $59K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.3% | 1,286 | 1,124 | $28K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.2% | 477 | 436 | $26K |
| 99423 | <1% | 389 | 344 | $17K | |
| 99358 | Prolong nursin fac eval 15m | <1% | 540 | 429 | $14K |
16 more codes
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 52 | $13K |
| 99205 | Prolong outpt/office vis | <1% | 129 | $13K |
| 99441 | <1% | 367 | $7K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 84 | $7K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 439 | $5K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 39 | $4K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 28 | $3K |
| M0244 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency | <1% | 16 | $3K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 15 | $1K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 14 | $1K |
| 99417 | Prolong home eval add 15m | <1% | 89 | $933.92 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 57 | $751.68 |
| 36000 | <1% | 94 | $705.62 | |
| 99350 | Prolong home eval add 15m | <1% | 15 | $460.00 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 13 | $68.90 |
| INVCD | 0% | 63 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialELFENBEIN, RON (MEDICAL DIRECTOR)